StockpollyBeta
Get App
Popularity #4,160
CLLS · NASDAQ · Biotechnology

Cellectis (ADR) (CLLS)

Develops gene-edited allogeneic CAR-T candidates and manufacturing capabilities.

$1.57
vs last close+0.06 (+3.97%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue005816131117351065
Cost of revenue052233222354
Gross profit0−527131091433711
212623242421232425252826
Research & development192622242421222324242321
302221222135
General & administrative302221222130
Other expenses−20−2−2−2−1−1−1−2−120
Operating income−21−31−21−17−11−11−14−108−17−27−25
3−3426−8−1217−4−14−7−982
Interest income502334322222
Interest expense2182222222222
Other non-operating income−50−28610−192125700
Income before tax−17−655−25−236−18−241−27−20−23
Income tax expense0−100010000−2−2
Net income from continuing operations−17−646−25−236−18−241−26−18−22
Discontinued operations0190000000000
Other adjustments000000000000
Net income−17−436−25−236−18−241−26−18−22
EPS, basic−$0.31−$0.67$0.08−$0.28−$0.23$0.06−$0.18−$0.24$0.01−$0.27−$0.18−$0.22
EPS, diluted−$0.31−$0.54$0.05−$0.28−$0.23$0.06−$0.18−$0.24$0.01−$0.27−$0.18−$0.22
Weighted average shares, basic56647290100100100100100100101101
Weighted average shares, diluted568010390100100100100100100101101
EBITDA−11−2612−19−1614−11−178−20−23−21
Depreciation & amortization455556555554
EBIT−16−317−24−218−16−223−25−27−25